Trevi Narrows Q3 Loss Amid Haduvio Development, Boosts Cash Reserves

TL;DR

**TRVI's cash infusion and reduced burn rate are a lifeline, but Haduvio's success is still a massive binary bet.**

AI Summary

Trevi Therapeutics, Inc. (TRVI) reported a net loss of $11.802 million for the three months ended September 30, 2025, an improvement from the $13.242 million net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $34.443 million, compared to $36.496 million in 2024. Research and development expenses decreased to $10.085 million for the quarter from $11.224 million year-over-year, and to $27.285 million for the nine months from $30.049 million. General and administrative expenses increased to $3.831 million for the quarter from $2.863 million, and to $11.823 million for the nine months from $9.232 million. The company's cash and cash equivalents significantly increased to $56.869 million as of September 30, 2025, from $34.097 million at December 31, 2024, largely due to $108.154 million in proceeds from a common stock offering and $10.757 million from warrant exercises. Marketable securities also rose to $138.058 million from $73.525 million. TRVI is heavily dependent on the successful development and commercialization of Haduvio, its sole product candidate, for chronic cough in patients with IPF, non-IPF ILD, and RCC, and expects to incur significant and increasing losses for the foreseeable future.

Why It Matters

For investors, Trevi's narrowed net loss and substantial increase in cash and marketable securities to $194.927 million provide a longer runway for its critical Haduvio clinical trials, particularly the planned Phase 3 program for chronic cough in IPF. This financial stability is crucial in the highly competitive and capital-intensive biopharmaceutical sector, where drug development failures are common. Employees benefit from the extended operational viability, while potential patients with chronic cough conditions await the outcome of Haduvio's development. The broader market will watch if Trevi can successfully navigate regulatory hurdles and commercialize Haduvio, potentially creating a new treatment option and impacting the competitive landscape for respiratory therapeutics.

Risk Assessment

Risk Level: high — Trevi Therapeutics is a clinical-stage biopharmaceutical company with no revenue, incurring significant losses ($34.443 million net loss for the nine months ended September 30, 2025). The company is entirely dependent on the successful development and commercialization of Haduvio, its sole product candidate, which faces lengthy, expensive, and uncertain clinical trials and regulatory approval processes. The drug label for Haduvio's active ingredient, nalbuphine, carries an opioid class warning for serious respiratory depression, posing a significant regulatory and commercialization risk.

Analyst Insight

Investors should monitor the progress of Haduvio's planned Phase 3 program and regulatory feedback closely. While the recent capital raise provides financial stability, the inherent risks of a single-product, clinical-stage biotech remain high. Consider this a speculative investment with potential for high reward if Haduvio succeeds, but also significant risk of capital loss if it fails.

Financial Highlights

net Income

-$11.802M

cash Position

$56.869M

Key Numbers

• $11.802M — Net Loss (Q3 2025) (Decreased from $13.242M in Q3 2024, indicating improved financial performance.)
• $34.443M — Net Loss (9 Months 2025) (Decreased from $36.496M in 9 Months 2024, showing a reduced burn rate.)
• $56.869M — Cash and Cash Equivalents (Increased significantly from $34.097M at Dec 31, 2024, bolstering liquidity.)
• $138.058M — Marketable Securities (Increased from $73.525M at Dec 31, 2024, further strengthening financial position.)
• $10.085M — Research and Development (Q3 2025) (Decreased from $11.224M in Q3 2024, potentially reflecting trial phasing or cost management.)
• $108.154M — Proceeds from Common Stock Offering (Major capital infusion in 2025, significantly improving cash position.)
• 128,230,134 — Common Stock Outstanding (As of October 31, 2025, reflecting dilution from recent equity offerings.)
• $189.788M — Total Stockholders' Equity (Increased from $99.644M at Dec 31, 2024, due to capital raises.)

Key Players & Entities

• Trevi Therapeutics, Inc. (company) — registrant
• Haduvio (company) — sole product candidate
• Endo, Inc. (company) — intellectual property licensor
• Nasdaq Stock Market LLC (regulator) — exchange where common stock is registered
• Securities and Exchange Commission (regulator) — filing oversight
• $11.802 million (dollar_amount) — net loss for Q3 2025
• $34.443 million (dollar_amount) — net loss for nine months ended Sept 30, 2025
• $56.869 million (dollar_amount) — cash and cash equivalents as of Sept 30, 2025
• $108.154 million (dollar_amount) — proceeds from common stock offering
• nalbuphine ER (company) — active ingredient in Haduvio

FAQ

Risk Factors

• Dependence on Haduvio [high — operational]: TRVI's future is heavily reliant on the successful development and commercialization of Haduvio, its sole product candidate. The company expects to incur significant and increasing losses for the foreseeable future, underscoring the high risk associated with this single-product dependency.
• Burn Rate and Future Funding Needs [high — financial]: Despite a reduced net loss in the first nine months of 2025 ($34.443 million vs. $36.496 million in 2024), the company continues to incur substantial operating losses. While cash and cash equivalents increased significantly to $56.869 million due to a stock offering, ongoing losses necessitate careful cash management and potential future capital raises.
• Clinical Trial Success and Regulatory Approval [high — regulatory]: The development of Haduvio involves complex clinical trials and requires stringent regulatory approval from bodies like the FDA. Any delays, adverse findings, or failure to obtain approval would severely impact TRVI's prospects.
• Market Acceptance and Competition [medium — market]: Even if Haduvio receives regulatory approval, its commercial success depends on market acceptance by physicians and patients, and its ability to compete effectively against existing or emerging treatments for chronic cough in IPF, non-IPF ILD, and RCC.
• Increased G&A Expenses [medium — financial]: General and administrative expenses increased to $3.831 million for Q3 2025 and $11.823 million for the nine months ended September 30, 2025, compared to prior periods. This rise, while potentially supporting growth initiatives, adds to the overall cost structure.

Industry Context

Trevi Therapeutics operates in the highly competitive biopharmaceutical industry, focusing on developing treatments for rare diseases and specific unmet medical needs. The development of novel therapies for conditions like Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD) requires substantial R&D investment and navigating a complex regulatory landscape. Success is often dependent on demonstrating significant clinical efficacy and safety compared to existing standards of care or placebo.

Regulatory Implications

As a clinical-stage biopharmaceutical company, TRVI faces significant regulatory hurdles. The development and approval process for its sole product candidate, Haduvio, by agencies like the FDA is lengthy, costly, and uncertain. Any adverse regulatory decisions or delays in the approval process pose a material risk to the company's future.

What Investors Should Do

1. Monitor clinical trial progress and regulatory updates for Haduvio.
2. Assess the company's cash burn rate and future financing needs.
3. Evaluate the competitive landscape for chronic cough treatments in IPF, ILD, and RCC.

Glossary

IPF

Idiopathic Pulmonary Fibrosis, a chronic lung disease characterized by scarring of lung tissue. (TRVI's product candidate, Haduvio, is being developed for patients with IPF, making this a key indication.)

ILD

Interstitial Lung Disease, a group of disorders that cause progressive scarring of lung tissue. (TRVI's product candidate, Haduvio, is also being developed for patients with non-IPF ILD, expanding its potential market.)

RCC

Rendu-Osler-Weber disease, also known as Hereditary Hemorrhagic Telangiectasia, a genetic disorder that affects blood vessels. (TRVI's product candidate, Haduvio, is being investigated for patients with RCC, representing another therapeutic area.)

Haduvio

Trevi Therapeutics' sole product candidate, currently under development for chronic cough in specific patient populations. (The success or failure of Haduvio is critical to the company's entire business model and future financial performance.)

Common Stock Offering

A sale of new shares of stock by a company to raise capital from investors. (TRVI raised $108.154 million through a common stock offering, significantly bolstering its cash reserves.)

Warrant Exercises

The process by which holders of stock warrants purchase shares of the company's stock at a specified price. (TRVI received $10.757 million from warrant exercises, contributing to its increased cash position.)

Year-Over-Year Comparison

Compared to the prior year, Trevi Therapeutics has shown a reduction in its net loss for both the third quarter ($11.802 million vs. $13.242 million) and the first nine months ($34.443 million vs. $36.496 million) of 2025, indicating improved cost management or operational efficiency. Research and development expenses have also decreased year-over-year, potentially reflecting shifts in trial phasing. However, general and administrative expenses have risen, increasing the overall cost structure. The company's liquidity has been substantially strengthened through a significant common stock offering and warrant exercises, leading to a considerable increase in cash and marketable securities.

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share TRVI The Nasdaq

Filing Documents

• trvi-20250930.htm (10-Q) — 2796KB
• trvi-ex10_1.htm (EX-10.1) — 66KB
• trvi-ex31_1.htm (EX-31.1) — 18KB
• trvi-ex32_1.htm (EX-32.1) — 12KB
• img64809683_0.jpg (GRAPHIC) — 39KB
• 0001193125-25-280166.txt ( ) — 10210KB
• trvi-20250930.xsd (EX-101.SCH) — 1133KB
• trvi-20250930_htm.xml (XML) — 1958KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 19 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 27 Item 4.

Controls and Procedures

Controls and Procedures 28 PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 28 Item 1A.

Risk Factors

Risk Factors 28 Item 5. Other Information 72 Item 6. Exhibits 72

—FINANCI AL INFORMATION

PART I—FINANCI AL INFORMATION

Condensed Consolidated Financi al Statements

Item 1. Condensed Consolidated Financi al Statements. Trevi Therapeutics, Inc. Condensed Consolida ted Balance Sheets (Amounts in thousands, except share and per share amounts) September 30, 2025 December 31, 2024 Assets Unaudited Current assets: Cash and cash equivalents $ 56,869 $ 34,097 Marketable securities 138,058 73,525 Prepaid expenses 1,375 939 Other current assets 1,997 867 Total current assets 198,299 109,428 Operating lease right-of-use assets 741 915 Property, equipment and leasehold improvements, net 213 157 Other non-current assets 103 243 Finance lease right-of-use assets — 157 Total assets $ 199,356 $ 110,900 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 2,709 $ 3,414 Accrued expenses 6,036 6,810 Operating lease liabilities 296 254 Finance lease liabilities — 31 Total current liabilities 9,041 10,509 Operating lease liabilities 527 747 Total liabilities 9,568 11,256 Commitments and contingencies ( Note 12) Stockholders' equity: Preferred stock: $ 0.001 par value; 5,000,000 shares authorized at September 30, 2025 and December 31, 2024; no shares issued or outstanding at September 30, 2025 and December 31, 2024. — — Common stock: $ 0.001 par value; 200,000,000 shares authorized at September 30, 2025 and December 31, 2024; and 128,215,113 and 93,602,631 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively. 128 94 Additional paid-in capital 511,118 386,534 Accumulated other comprehensive income 30 61 Accumulated deficit ( 321,488 ) ( 287,045 ) Total stockholders' equity 189,788 99,644 Total liabilities and stockholders' equity $ 199,356 $ 110,900 The accompanying notes are an integral part of these condensed consolidated financial statements. 1 Trevi Therapeutics, Inc. Condensed Consolidated State

View Full Filing

View this 10-Q filing on SEC EDGAR